Dermata Therapeutics (DRMA) News Today $1.08 +0.03 (+2.86%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Dermata Therapeutics receives FDA approval for Xyngari proprietary nameDecember 18 at 12:21 PM | markets.businessinsider.comDermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 4, 2024 | finance.yahoo.comDermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024November 11, 2024 | globenewswire.comWhy Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving PremarketSeptember 16, 2024 | benzinga.comMaxim cuts Dermata Therapeutics stock target, retains buy on dilution riskAugust 23, 2024 | investing.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | finance.yahoo.com3 Penny Stocks to Watch Now, 8/6/24August 6, 2024 | msn.comDermata Therapeutics (NASDAQ:DRMA) Stock, Short Interest ReportJuly 26, 2024 | benzinga.comDermata Therapeutics (NASDAQ:DRMA) Stock Quotes, Forecast and News SummaryJuly 25, 2024 | benzinga.comActinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer TreatmentJuly 25, 2024 | theglobeandmail.comDermata Therapeutics Shares Are Trading Over 100%: What You Need To KnowJuly 24, 2024 | benzinga.comWhy Is Dermata Therapeutics (DRMA) Stock Up 200% Today?July 24, 2024 | investorplace.comDermata Therapeutics announces warrant exercise and new issuanceMay 19, 2024 | uk.investing.comDRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024May 16, 2024 | investorplace.comDermata Therapeutics, Inc. (DRMAW)February 11, 2024 | ca.finance.yahoo.comPresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register NowFebruary 6, 2024 | finance.yahoo.comDermata Therapeutics Inc DRMAFebruary 4, 2024 | morningstar.comDermata to Present at the Emerging Growth Conference on February 7, 2024February 1, 2024 | finance.yahoo.comDermata stock soars on patent issuance, partnership talksJanuary 7, 2024 | msn.comDow Turns Lower; ISM Services PMI Falls In DecemberJanuary 5, 2024 | msn.comWhy Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?January 5, 2024 | msn.comWhy Is Dermata Therapeutics (DRMA) Stock Up 62% Today?January 5, 2024 | investorplace.comStocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion PharmaceuticalsJanuary 4, 2024 | marketwatch.comDermata Therapeutics Shares Surge 120% on Patent Issued in JapanJanuary 4, 2024 | marketwatch.comWhy Dermata Therapeutics Stock Took Off After-HoursJanuary 4, 2024 | msn.comDermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of HyperhidrosisJanuary 4, 2024 | finance.yahoo.comDermata Therapeutics: Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 21, 2023 | finanznachrichten.deDermata Therapeutics Stock (NASDAQ:DRMA) Dividends: History, Yield and DatesDecember 20, 2023 | benzinga.comDermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 20, 2023 | finance.yahoo.comDermata Therapeutics Inc.December 13, 2023 | thestreet.comDermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesNovember 16, 2023 | finance.yahoo.comDermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 ProtocolsNovember 16, 2023 | finance.yahoo.comDermata Therapeutics GAAP EPS of -$0.54November 10, 2023 | msn.comDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 9, 2023 | finance.yahoo.comDermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne TrialOctober 26, 2023 | finance.yahoo.comDermata to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 31, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comDermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe AcneJune 27, 2023 | finance.yahoo.comDermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETJune 13, 2023 | finance.yahoo.comJournal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne ResultsJune 8, 2023 | finance.yahoo.comDermata Therapeutics: Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne ResultsJune 8, 2023 | finanznachrichten.deDermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesMay 26, 2023 | finance.yahoo.comDermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesMay 24, 2023 | finance.yahoo.comDermata Therapeutics announces $1.8M offering priced ATMMay 24, 2023 | msn.comDermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesMay 24, 2023 | finance.yahoo.comDermata Therapeutics Shares Rally Premarket on DMT310 Update >DRMAMay 12, 2023 | marketwatch.comDermata Therapeutics GAAP EPS of -$2.27May 11, 2023 | seekingalpha.comDermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comDermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studiesMay 9, 2023 | proactiveinvestors.comDermata (DRMA) Gains on Positive FDA Response for Acne CandidateApril 21, 2023 | finance.yahoo.com Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss. Click Here to get the full details about Crypto’s Hidden Gem DRMA Media Mentions By Week DRMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRMA News Sentiment▼0.480.59▲Average Medical News Sentiment DRMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRMA Articles This Week▼10▲DRMA Articles Average Week Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GNPX News Today BCLI News Today ENSC News Today BFRI News Today AYTU News Today ADXN News Today VIRX News Today CDT News Today CERO News Today SNGX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRMA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRMA Stock Alerts